Reduction of C-reactive protein with isoflavone supplement reverses endothelial dysfunction in patients with ischaemic stroke.

AIMS To investigate the effect of oral isoflavone supplement on vascular endothelial function in patients with established cardiovascular disease. METHODS AND RESULTS A randomized, double-blinded, placebo-controlled trial was performed to determine the effects of isoflavone supplement (80 mg/day, n = 50) vs. placebo (n = 52) for 12 weeks on brachial flow-mediated dilatation (FMD) in patients with prior ischaemic stroke. Compared with controls, FMD at 12 weeks was significantly greater in isoflavone-treated patients [treatment effect 1.0%, 95% confidence interval (95% CI) 0.1-2.0, P = 0.035]. Adjusted for baseline differences in FMD, isoflavone treatment was independently associated with significantly less impairment of FMD at 12 weeks (odds ratio 0.32, 95% CI 0.13-0.80, P = 0.014). The absolute treatment effect of isoflavone on brachial FMD was inversely related to baseline FMD (r = -0.51, P < 0.001), suggesting that vasoprotective effect of isoflavone was more pronounced in patients with more severe endothelial dysfunction. Moreover, isoflavone treatment for 12 weeks resulted in a significant decrease in serum high-sensitivity (hs)-C-reactive protein level (treatment effect -1.7 mg/L, 95% CI -3.3 to -0.1, P = 0.033). Nevertheless, isoflavone did not have any significant treatment effects on nitroglycerin-mediated dilatation, blood pressure, heart rate, serum levels of fasting glucose and insulin, haemoglobin A1c, and oxidative stress as determined by serum superoxide dismutase, 8-isoprostane, and malondialdehyde (all P > 0.05). CONCLUSION This study demonstrated that 12 week isoflavone treatment reduced serum hs-C-reactive protein and improved brachial FMD in patients with clinically manifest atherosclerosis, thus reversing their endothelial dysfunction status. These findings may have important implication for the use of isoflavone for secondary prevention in patients with cardiovascular disease, on top of conventional interventions.

[1]  Nader Rifai,et al.  Inflammation, Statin Therapy, and Risk of Stroke After an Acute Coronary Syndrome in the MIRACL Study , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[2]  C. Lau,et al.  Isoflavone intake in persons at high risk of cardiovascular events: implications for vascular endothelial function and the carotid atherosclerotic burden. , 2007, The American journal of clinical nutrition.

[3]  L. Newby,et al.  Age Moderates the Short-Term Effects of Transdermal 17β-Estradiol on Endothelium-Dependent Vascular Function in Postmenopausal Women , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[4]  C. Lehmann,et al.  Effects of low habitual cocoa intake on blood pressure and bioactive nitric oxide: a randomized controlled trial. , 2007, JAMA.

[5]  R. Sacco,et al.  The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. , 2007, Atherosclerosis.

[6]  H. Tse,et al.  Burden of carotid atherosclerosis in patients with stroke: relationships with circulating endothelial progenitor cells and hypertension , 2007, Journal of Human Hypertension.

[7]  Shuangge Ma,et al.  Antihypertensive medications and C-reactive protein in the multi-ethnic study of atherosclerosis. , 2007, American journal of hypertension.

[8]  K. Reynolds,et al.  A meta-analysis of the effect of soy protein supplementation on serum lipids. , 2006, The American journal of cardiology.

[9]  J. Moya,et al.  Endothelial dysfunction, intima–media thickness and coronary reserve in relation to risk factors and Framingham score in patients without clinical atherosclerosis , 2006, Journal of hypertension.

[10]  S. Hirsch,et al.  Soy isoflavones affect platelet thromboxane A2 receptor density but not plasma lipids in menopausal women. , 2006, Maturitas.

[11]  K. Prasad.  C-reactive protein (CRP)-lowering agents. , 2006, Cardiovascular drug reviews.

[12]  F. Sacks,et al.  Soy Protein, Isoflavones, and Cardiovascular Health: An American Heart Association Science Advisory for Professionals From the Nutrition Committee , 2006, Circulation.

[13]  C. Nowson,et al.  Fruit and vegetable consumption and stroke: meta-analysis of cohort studies , 2006, The Lancet.

[14]  H. Sies,et al.  Acute consumption of flavanol-rich cocoa and the reversal of endothelial dysfunction in smokers. , 2005, Journal of the American College of Cardiology.

[15]  Imran Y. Khan,et al.  Dietary soy isoflavone‐induced increases in antioxidant and eNOS gene expression lead to improved endothelial function and reduced blood pressure in vivo , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  X. Shu,et al.  Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women. , 2005, Archives of internal medicine.

[17]  M. Wolzt,et al.  Endurance training increases the number of endothelial progenitor cells in patients with cardiovascular risk and coronary artery disease. , 2005, Atherosclerosis.

[18]  M. Spitz,et al.  Dietary phytoestrogens and lung cancer risk. , 2005, JAMA.

[19]  Robert Adams,et al.  Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. , 2005, Stroke.

[20]  A. Vollmar,et al.  The soy isoflavone genistein induces a late but sustained activation of the endothelial nitric oxide‐synthase system in vitro , 2005, British journal of pharmacology.

[21]  E. D. de Haan,et al.  Effect of Soy Protein Containing Isoflavones on Cognitive Function , Bone Mineral Density , and Plasma Lipids in Postmenopausal Women , 2004 .

[22]  X. Shu,et al.  Soya food intake and risk of endometrial cancer among Chinese women in Shanghai: population based case-control study , 2004, BMJ : British Medical Journal.

[23]  G. Mancini.  Vascular structure versus function: is endothelial dysfunction of independent prognostic importance or not? , 2004, Journal of the American College of Cardiology.

[24]  H. Tse,et al.  Endothelial function in obstructive sleep apnea and response to treatment. , 2004, American journal of respiratory and critical care medicine.

[25]  A. Ignaszewski,et al.  The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. , 2003, Journal of the American College of Cardiology.

[26]  A. Maggi,et al.  Diabetes Undermines Estrogen Control of Inducible Nitric Oxide Synthase Function in Rat Aortic Smooth Muscle Cells Through Overexpression of Estrogen Receptor-&bgr; , 2003, Circulation.

[27]  J. Potter,et al.  Soy isoflavones do not modulate circulating insulin-like growth factor concentrations in an older population in an intervention trial. , 2003, The Journal of nutrition.

[28]  Sidney C. Smith,et al.  MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION , 2003 .

[29]  D. Cucinotta,et al.  Effect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study. , 2003, The American journal of medicine.

[30]  R. Grubb,et al.  Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association , 2003, Stroke.

[31]  Douglas G. Altman,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[32]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[33]  B. Fagerberg,et al.  Endothelium‐dependent flow‐mediated vasodilatation, insulin resistance and the metabolic syndrome in 60‐year‐old men , 2002, Journal of internal medicine.

[34]  E. Kilpatrick,et al.  Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes. , 2002, Diabetes care.

[35]  M. Anthony.  Phytoestrogens and cardiovascular disease: where's the meat? , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[36]  D. Altavilla,et al.  The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women. , 2002, Atherosclerosis.

[37]  D. Grobbee,et al.  Higher Usual Dietary Intake of Phytoestrogens Is Associated With Lower Aortic Stiffness in Postmenopausal Women , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[38]  P. Whelton,et al.  Legume consumption and risk of coronary heart disease in US men and women: NHANES I Epidemiologic Follow-up Study. , 2001, Archives of internal medicine.

[39]  H. Teede,et al.  Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women. , 2001, The Journal of clinical endocrinology and metabolism.

[40]  F. Perticone,et al.  Prognostic Significance of Endothelial Dysfunction in Hypertensive Patients , 2001, Circulation.

[41]  T. Sanders,et al.  The Phytoestrogen Genistein Produces Acute Nitric Oxide–Dependent Dilation of Human Forearm Vasculature With Similar Potency to 17&bgr;-Estradiol , 2001, Circulation.

[42]  A. Vincent,et al.  Soy isoflavones: are they useful in menopause? , 2000, Mayo Clinic proceedings.

[43]  S. Fichtlscherer,et al.  Elevated C-Reactive Protein Levels and Impaired Endothelial Vasoreactivity in Patients With Coronary Artery Disease , 2000, Circulation.

[44]  J. Simons,et al.  Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. , 2000, The American journal of cardiology.

[45]  J. Cooke,et al.  Phytoestrogens and cardiovascular health. , 2000, Journal of the American College of Cardiology.

[46]  T. Lakka,et al.  Risk of acute coronary events according to serum concentrations of enterolactone: a prospective population-based case-control study , 1999, The Lancet.

[47]  J. Viikari,et al.  HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. , 1999, Atherosclerosis.

[48]  J. Crouse,et al.  A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. , 1999, Archives of internal medicine.

[49]  A. Dart,et al.  Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[50]  James W. Anderson,et al.  Meta-analysis of the effects of soy protein intake on serum lipids. , 1995, The New England journal of medicine.

[51]  A. Quyyumi,et al.  Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. , 1995, Circulation.

[52]  L. Lind.  Arterial compliance influences the measurement of flow-mediated vasodilation, but not acetylcholine-mediated forearm blood flow. The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. , 2007, Atherosclerosis.

[53]  P. Kris-Etherton,et al.  Soy protein with or without isoflavones: in search of a cardioprotective mechanism of action. , 2005, The American journal of clinical nutrition.

[54]  D. Grobbee,et al.  Randomized controlled trial of the effects of soy protein containing isoflavones on vascular function in postmenopausal women. , 2005, The American journal of clinical nutrition.

[55]  X. Shu,et al.  Validity and reproducibility of the food frequency questionnaire used in the Shanghai Women's Health Study , 2004, European Journal of Clinical Nutrition.

[56]  R. Andriantsitohaina,et al.  Age-related endothelial dysfunction : potential implications for pharmacotherapy. , 2003, Drugs & aging.

[57]  Ose,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .